Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study

References

• Bassetti M, Peghin M, Pecori D. The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2016;29:583–594. doi:10.1097/QCO.0000000000000314
   PubMed Web of Science ®Google Scholar
• Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215:S28–36. doi:10.1093/infdis/jiw282
   PubMed Web of Science ®Google Scholar
• Jean -S-S, Harnod D, Hsueh P-R. Global threat of carbapenem-resistant Gram-negative bacteria. Front Cell Infect Microbiol. 2022;12:823684. doi:10.3389/fcimb.2022.823684
   PubMed Web of Science ®Google Scholar
• Novelli A, Giacomo PD, Rossolini GM, Tumbarello M. Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination. Expert Rev Anti-Infect Ther. 2020;18(7):643–655. doi:10.1080/14787210.2020.1756775
   PubMed Web of Science ®Google Scholar
• Bagheri-Nesami M, Rafiei A, Eslami G, et al. Assessment of extended-spectrum β-lactamases and integrons among Enterobacteriaceae in device-associated infections: multicenter study in north of Iran. Antimicrob Resist Infect Control. 2016;5:52. doi:10.1186/s13756-016-0143-2
   Web of Science ®Google Scholar
• Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme. Int J Antimicrob Agents. 2018;52:144–150.
   PubMed Web of Science ®Google Scholar
• Süzük Yıldız S, Kaşkatepe B, Şimşek H, Sarıgüzel FM. High rate of colistin and fosfomycin resistance among carbapenemase-producing Enterobacteriaceae in Turkey. Acta Microbiol Immunol Hung. 2019;66(1):103–112. doi:10.1556/030.65.2018.042
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Pop-Vicas AE. Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have? Crit Care. 2014;18(3):229. doi:10.1186/cc13949
   PubMed Web of Science ®Google Scholar
• Maraki S, Mavromanolaki VE, Moraitis P, et al. Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2021;40(8):1755–1759. doi:10.1007/s10096-021-04197-3
   PubMed Web of Science ®Google Scholar
• Katip W, Yoodee J, Uitrakul S, Oberdorfer P. Efficacy of loading dose colistin versus carbapenems for treatment of extended spectrum beta lactamase producing Enterobacteriaceae. Sci Rep. 2021;11(1):18. doi:10.1038/s41598-020-78098-4
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Clinical efficacy and nephrotoxicity of the loading dose colistin for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients. Pharmaceutics. 2021;14(1):31. doi:10.3390/pharmaceutics14010031
   PubMed Web of Science ®Google Scholar
• Katip W, Oberdorfer P, Kasatpibal N. Effectiveness and nephrotoxicity of loading dose colistin-meropenem versus loading dose colistin-imipenem in the treatment of carbapenem-resistant Acinetobacter baumannii infection. Pharmaceutics. 2022;14(6):1266. doi:10.3390/pharmaceutics14061266
   PubMed Web of Science ®Google Scholar
• Aghamali M, Sedighi M, Zahedi Bialvaei A, et al. Fosfomycin: mechanisms and the increasing prevalence of resistance. J Med Microbiol. 2019;68(1):11–25. doi:10.1099/jmm.0.000874
   PubMed Web of Science ®Google Scholar
• Ohkoshi Y, Sato T, Suzuki Y, et al. Mechanism of reduced susceptibility to fosfomycin in Escherichia coli clinical isolates. Biomed Res Int. 2017;2017:5470241. doi:10.1155/2017/5470241
   Web of Science ®Google Scholar
• Garallah ET, Al-Jubori SS. Surveillance of murA and the plasmid-mediated fosfomycin resistance fosA gene in uropathogenic E. coli isolates from UTI patients. Gene Rep. 2020;21(7):100872. doi:10.1016/j.genrep.2020.100872
   Web of Science ®Google Scholar
• Mashaly G-S. Activity of fosfomycin in extended-spectrum beta-lactamases producing Klebsiella pneumoniae from hospital acquired urinary tract infections. Open J Med Microbiol. 2016;6:104–110. doi:10.4236/ojmm.2016.63014
   Google Scholar
• Foad MF. Phenotypic detection and antimicrobial susceptibility profile of ESBL, AmpC and carbapenemase producing gram-negative isolates from outpatient clinic specimens. Int J Curr Microbiol App Sci. 2016;5(1):740–752. doi:10.20546/ijcmas.2016.501.075
   Google Scholar
• Lee Y, Kim J, Trinh S. Meropenem-Vaborbactam (Vabomere™): another option for carbapenem-resistant Enterobacteriaceae. PT. 2019;44:110–113.
   PubMedGoogle Scholar
• Tumbarello M, Raffaelli F, Cascio A, et al. Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study. JAC Antimicrob Resist. 2022;4(1):dlac022. doi:10.1093/jacamr/dlac022
   PubMedGoogle Scholar
• Forteza Guillot M, Martín Cerezuela M, Ramírez P. New evidence in severe pneumonia: meropenem-vaborbactam. Rev Esp Quimioter. 2022;35(Suppl1):43–45. doi:10.37201/req/s01.10.2022
   Google Scholar
• Clinical and Laboratory Standards Institute (CLSI. Performance Standards for Antimicrobial Susceptibility Testing CLSI Supplement M100. 31st ed. Wayne, PA: CLSI; 2021.
   Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 11th ed. Wayne, PA: CLSI; 2018.
   Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0; 2022. Available from: http://www.eucast.org. Accessed October 21, 2022.
   Google Scholar
• Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70(1):119–123. doi:10.1016/j.diagmicrobio.2010.12.002
   PubMed Web of Science ®Google Scholar
• Khosravi AD, Motahar M, Abbasi Montazeri E. The frequency of class1 and 2 integrons in Pseudomonas aeruginosa strains isolated from burn patients in a burn center of Ahvaz, Iran. PLoS One. 2017;12(8):e0183061. doi:10.1371/journal.pone.0183061
   PubMed Web of Science ®Google Scholar
• Li Y, Zheng B, Li Y, Zhu S, Xue F, Liu J. Antimicrobial susceptibility and molecular mechanisms of fosfomycin resistance in clinical Escherichia coli isolates in mainland China. PLoS One. 2015;10(8):e0135269. doi:10.1371/journal.pone.0135269
   PubMed Web of Science ®Google Scholar
• Kotb S, Lyman M, Ismail G, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in Egyptian intensive care units using National Healthcare–associated infections surveillance data, 2011–2017. Antimicrob Resist Infect Control. 2020;9(1):1–9. doi:10.1186/s13756-019-0639-7
   PubMed Web of Science ®Google Scholar
• Raheel AS, Mohamed HA, Hessam WF, Abbadi SH, El Sayed AE. Detection of carbapenemase enzymes and genes among carbapenem-resistant Enterobacteriaceae isolates in Suez Canal University Hospitals in Ismailia, Egypt. Microbes and Infect Dis. 2020;1((1)):24–33.
   Google Scholar
• Khalil HS, Wahab MAAE. Risk factors, phenotypic and genotypic characterization of carbapenem resistant Enterobacteriaceae in Tanta University Hospitals, Egypt. Int J Infect Control. 2016;12(2). doi:10.3396/ijic.v12i2.15905
   Google Scholar
• Kamel NA, El-Tayeb WN, El-Ansary MR, Mansour MT, Aboshanab KM. Phenotypic screening and molecular characterization of carbapenemase-producing Gram-negative bacilli recovered from febrile neutropenic pediatric cancer patients in Egypt. PLoS One. 2018;13(8):e0202119. doi:10.1371/journal.pone.0202119
   Web of Science ®Google Scholar
• Bitew A, Tsige E. High prevalence of multidrug-resistant and extended-spectrum β-lactamase-producing Enterobacteriaceae: a cross-sectional study at Arsho advanced medical laboratory, Addis Ababa, Ethiopia. J Trop Med. 2020;2020:6167234.
   Web of Science ®Google Scholar
• El-Kholy A, El-Mahallawy HA, Elsharnouby N, Abdel Aziz M, Helmy AM, Kotb R. Landscape of multidrug-resistant gram-negative infections in Egypt: survey and literature review. Infect Drug Resist. 2021;14:1905–1920. doi:10.2147/IDR.S298920
   PubMed Web of Science ®Google Scholar
• Shanmugam P, Meenakshisundaram J, Jayaraman P. blaKPC gene detection in clinical isolates of carbapenem resistant Enterobacteriaceae in a tertiary care hospital. J Clin Diagn Res. 2013;7:2736–2738. doi:10.7860/JCDR/2013/7759.3747
   Google Scholar
• Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC producing, multidrug-resistant and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61:e00567–17. doi:10.1128/AAC.00567-17
   PubMed Web of Science ®Google Scholar
• Castanheira M, Doyle TB, Kantro V, Mendes RE, Shortridge D. Meropenem-vaborbactam activity against carbapenem resistant Enterobacterales isolates collected in U.S. hospitals during 2016 to 2018. Antimicrob Agents Chemother. 2020;64:e01951–19. doi:10.1128/AAC.01951-19
   PubMed Web of Science ®Google Scholar
• Carvalhaes CG, Shortridge D, Sader HS, Castanheira M. Activity of Meropenem-vaborbactam against bacterial isolates causing pneumonia in patients in U.S. hospitals during 2014 to 2018. Antimicrob Agents Chemother. 2020;64(3):e02177–19. doi:10.1128/AAC.02177-19
   Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x
   PubMed Web of Science ®Google Scholar
• El-Kholy AA, Girgis SA, Shetta MAF, Abdel-Hamid DH, Elmanakhly AR. Molecular characterization of multidrug-resistant Gram-negative pathogens in three tertiary hospitals in Cairo, Egypt. Eur J Clin Microbiol Infect Dis. 2020;39(5):987–992. doi:10.1007/s10096-020-03812-z
   PubMed Web of Science ®Google Scholar
• Alkofide H, Alhammad AM, Alruwaili A, et al. Multidrug-resistant and extensively drug-resistant Enterobacteriaceae: prevalence, treatments, and outcomes-A retrospective cohort study. Infect Drug Resist. 2020;13:4653–4662.
   PubMed Web of Science ®Google Scholar
• Tekele SG, Teklu DS, Legese MH, et al. Multidrug-resistant and carbapenemase-producing Enterobacteriaceae in Addis Ababa, Ethiopia. Biomed Res Int. 2021;2021:9999638. doi:10.1155/2021/9999638
   Web of Science ®Google Scholar
• Bandyr A, Tantry B. ESBL activity, MDR, and carbapenem resistance among predominant Enterobacterales isolated in 2019. Antibiotics. 2021;10(6):744. doi:10.3390/antibiotics10060744
   Web of Science ®Google Scholar
• Tawfick MM, Alshareef WA, Bendary HA, Elmahalawy H, Abdulall AK. The emergence of carbapenemase blaNDM genotype among carbapenem-resistant Enterobacteriaceae isolates from Egyptian cancer patients. Eur J Clin Microbiol Infect Dis. 2020;39(7):1251–1259. doi:10.1007/s10096-020-03839-2
   Web of Science ®Google Scholar
• Moghnieh RA, Kanafani ZA, Tabaja HZ, Sharara SL, Awad LS, Kanj SS. Epidemiology of common resistant bacterial pathogens in the countries of the Arab League. Lancet Infect Dis. 2018;18(12):e379–e394. doi:10.1016/S1473-3099(18)30414-6
   PubMed Web of Science ®Google Scholar
• Gupta V, Ye G, Olesky M, Lawrence K, Murray J, Yu K. National prevalence estimates for resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States. Int J Infect Dis. 2019;85:203–211.
   PubMed Web of Science ®Google Scholar
• Qamar S, Shaheen N, Shakoor S, Farooqi J, Jabeen K, Hasan R. Frequency of colistin and fosfomycin resistance in carbapenem-resistant Enterobacteriaceae from a tertiary care hospital in Karachi. Infect Drug Resist. 2017;10:231–236.
   Web of Science ®Google Scholar
• Alexander BT, Marschall J, Tibbetts RJ, Neuner EA, Dunne WM, Ritchie DJ. Treatment and clinical outcomes of urinary tract infections caused by KPC producing Enterobacteriaceae in a retrospective cohort. Clin Ther. 2012;34:1314–1323.
   PubMed Web of Science ®Google Scholar
• Pogue JM, Marchaim D, Abreu-Lanfranco O, et al. Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008–10. J Antibiot. 2013;66:625–627.
   Web of Science ®Google Scholar
• Kaase M, Szabados F, Anders A, Gatermann SG. Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany. J Clin Microbiol. 2014;52(6):1893–1897.
   PubMed Web of Science ®Google Scholar
• White BP, Stover KR, Barber KE, Galloway RC, Sullivan DC, King ST. Mechanisms of fosfomycin resistance in carbapenem-resistant Enterobacter sp. Int J Antimicrob Agents. 2017;50(5):690–692. doi:10.1016/j.ijantimicag
   PubMed Web of Science ®Google Scholar
• Liu P, Chen S, Wu ZY, Qi M, Li XY, Liu CX. Mechanisms of fosfomycin resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist. 2020;22:238–243. doi:10.1016/j.jgar.2019.12.019
   Web of Science ®Google Scholar
• Elliott ZS, Barry KE, Cox HL, et al. The role of fosA in challenges with fosfomycin susceptibility testing of multispecies Klebsiella pneumoniae carbapenemase-producing clinical isolates. J Clin Microbiol. 2019;57(10):e00634–19. doi:10.1128/JCM.00634-19
   Web of Science ®Google Scholar
• Sun F, Chen S, Qiu X, et al. Antibacterial activity of fosfomycin against uropathogens. Chemother. 2014;60:157–161. doi:10.1159/000371734
   Web of Science ®Google Scholar
• Chen J, Wang D, Ding Y, Zhang L, Li X. Molecular epidemiology of plasmid-mediated fosfomycin resistance gene determinants in Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae isolates in China. Microb Drug Resist. 2019;25(2):251–257. doi:10.1089/mdr.2018.0137
   Web of Science ®Google Scholar
• Mosime LB, Newton-Foot M, Nel P. Fosfomycin resistance in community-acquired urinary pathogens from Western Cape, South Africa. S Afr J Infect Dis. 2022;37(1):a321. doi:10.4102/sajid.v37i1.321
   Web of Science ®Google Scholar
• Iman FEG, Marwa AM, Doaa AY. Phenotypic and genotypic methods for detection of metallo beta lactamases among carbapenem resistant Enterobacteriaceae clinical isolates in Alexandria Main University Hospital. Afr J Microbiol Res. 2016;10:32–40. doi:10.5897/AJMR2015.7821
   Google Scholar
• Kinn PM, Chen DJ, Gihring TM, et al. In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance. Diagn Microbiol Infect Dis. 2019;93(3):258–260. doi:10.1016/j.diagmicrobio.2018.09.017
   PubMed Web of Science ®Google Scholar
• Castanheira M, Doyle TB, Deshpande LM, Mendes RE, Sader HS. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. Int J Antimicrob Agents. 2021;58(5):106439. doi:10.1016/j.ijantimicag.2021.106439
   PubMed Web of Science ®Google Scholar
• Wanla W, Katip W, Supakul S, Apiwatnakorn P, Khamsarn S. Effects of an antimicrobial restriction system on appropriate carbapenem use in a hospital without infectious diseases consultation. Int J Gen Med. 2017;10:443–449. doi:10.2147/IJGM.S145133
   PubMed Web of Science ®Google Scholar